1. Scrip
  2. >>Business
  3. >>Strategy

What Happens After the Device IPO?

 
• By Tom Salemi

Investors love to remind everyone that IPOs are financing events, not exiting events, using the mantra to put off Judgment Day for their investments. So how have device companies fared after the recent spate of IPOs?

Perhaps a day once existed when medical device investors could call an IPO purely an exiting event. But for years now device investors—and their cousins on the biopharmaceutical side—have recognized an IPO for what it often is—an opportunity to get a little breathing room by having someone else help to pay the bills.

Even after the IPO, device VCs frequently maintain their stakes in their publicly traded companies until those businesses begin launching...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

MBX Awaits Value-Creating Milestones, With Phase II Hypoparathyroidism Data Due Any Day

 
• By Mandy Jackson

MBX Biosciences uses its Precision Endocrine Peptide (PEP) platform to create hormone therapeutics with improved efficacy, durability and tolerability in rare diseases and obesity.

The Expanding MASH Market: How Rezdiffra, Wegovy Might Coexist

 
• By Joseph Haas

FDA approval of Novo Nordisk's Wegovy for MASH was almost as anticipated as approval of the first drug, Madrigal's Rezdiffra. Now, the MASH treatment paradigm should evolve.

Deal Watch: XOMA Buys Troubled Alkermes-Spinout Mural Oncology

 
• By Joseph Haas, Xu Hu, and Lisa Takagi

Plus deals involving Fosun/Accro, Fosun/Sitala, RemeGen/Santen, Firebird/Solasia and more, including tech transfer.

Norway’s Nykode Upbeat About Cancer Vaccines After Tough Year

 
• By Kevin Grogan

The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.

More from Business

Novo Adds Another Prong To Its RNA Ambitions With Replicate Deal

 
• By Jessica Merrill

Replicate is a clinical-stage company developing a next-generation self-replicating RNA technology. CEO Nathanial Wang talked to Scrip about the deal.

Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals

 
• By Andrew McConaghie

Superluminal’s CEO Cony D’Cruz believes its focus on GPCRs has already yielded a best-in-class obesity candidate for its own pipeline, as well as its $1bn- plus deal with Eli Lilly.

Norway’s Nykode Upbeat About Cancer Vaccines After Tough Year

 
• By Kevin Grogan

The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.